
News|Videos|August 1, 2023
Clinical Pearls: Treating Different Patient Populations in NSCLC
Author(s)Joshua K. Sabari, MD, Narjust Florez, MD
Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































